Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.

Inclusion Criteria: * CLL according to national guidelines (Lymphoma.dk). * Unmutated IGHV gene according to ERIC recommendations.(25) * No prior CLL directed treatment * Age ≥ 18 * Eastern cooperative oncology group (ECOG) performance status of 0 or 1 * No life-threatening conditions * Adequate bone marrow function: Neutrophils \> 1,0 x 109/l; Platelets \> 100 x 109/l * Adequate renal function: Glomeruli filtration rate (eGFR)/1,73 m2 \> 50 mL/min * Adequate liver function: Aspartate Aminotransferase \< 100 U/L * For fertile women: agreement to use contraceptive methods with a failure rate of \< 1% per year during the treatment period and for at least 120 days after the last treatment. * For men: agreement to use contraceptive measures and agreement to refrain from donating sperm. Exclusion Criteria: * Other active malignant diseases requiring treatment. * Significant medical condition per investigators judgement e.g. severe Asthma or chronic obstructive lung disease (COLD), poorly regulated heart condition, insulin dependent diabetes mellitus. * Acute or chronic viral/bacterial infection e.g. human immunodeficiency virus (HIV), Cytomegalo virus (CMV), Epstein-barr virus (EBV), hepatitis or tuberculosis * Serious known allergies or earlier anaphylactic reactions. * Known sensibility towards Montanide ISA51 * Any active autoimmune diseases e.g. autoimmune neutropenia, thrombocytopenia or hemolytic anemia, systemic lupus erythematosus, scleroderma, myasthenia gravis, autoimmune glomerulonephritis, autoimmune adrenal deficiency, autoimmune thyroiditis etc. * Pregnant and breastfeeding women. * Fertile women not using secure contraception with a failure rate less than \< 1% * Psychiatric disorders that according to the investigator could influence compliance. * Treatment with other experimental drugs